vTv Therapeutics Q2 FY26 net loss widens to $13.1 million; R&D expenses more than doubled to $8.8 million

Reuters2026/08/06 12:05

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

vTv Therapeutics posted a Q2 net loss attributable to shareholders of USD 13.1 million, widening from USD 6 million a year earlier.
R&D expense more than doubled to USD 8.8 million; G&A expense rose 43.1% to USD 5.2 million.
Cash and cash equivalents totaled USD 86.6 million at June 30, down from USD 88.9 million at Dec. 31.
Phase 3 CATT1 trial enrollment is expected to finish in Q3 2026; vTv expects cash to fund operations through the topline readout.
Phase 2a Hybrid CATT1 trial is slated to start before year-end 2026; a cadisegliatin-focused KOL event is planned for Q4 2026.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. vTv Therapeutics Inc. published the original content used to generate this news brief on August 06, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

vTv Therapeutics Q2 FY26 net loss widens to $13.1 million; R&D expenses more than doubled to $8.8 million

You may also like

Crypto prices